Shield Therapeutics (LSE:STX) announced that China’s National Medical Products Administration (NMPA) has formally accepted a marketing authorisation application for its ferric maltol therapy, ACCRUFeR. The application was submitted by its regional partner, Beijing Aosaikang Pharmaceutical.
The filing is supported by clinical data previously reviewed by the U.S. Food and Drug Administration, as well as results from a Phase 3 study in Chinese adults suffering from iron deficiency anaemia associated with inflammatory bowel disease who are intolerant to conventional oral iron treatments. The trial demonstrated favourable efficacy and tolerability outcomes.
Acceptance of the application marks a significant regulatory milestone and positions Shield to enter China’s expanding iron deficiency anaemia market. The sector is projected to grow from approximately $280 million in 2022 to more than $600 million by 2030, offering substantial commercial potential if approval is secured.
The development would further broaden ACCRUFeR’s international footprint and strengthen Shield’s presence in Asia through its established licensing network. A successful approval in China would complement existing commercial and partnership arrangements in other major markets.
From an investment perspective, the company’s outlook is shaped by strong technical momentum and constructive corporate progress. However, ongoing financial pressures and valuation concerns remain key risk factors. While strategic regulatory advances provide optimism, underlying financial stability continues to be a critical consideration for investors.
More about Shield Therapeutics
Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on treating iron deficiency and iron deficiency anaemia with its oral ferric maltol product, marketed as ACCRUFeR in the United States and FeRACCRU in other territories. The group commercialises ACCRUFeR in the U.S. through Viatris and has licensed rights across Europe, Canada, Asia-Pacific and Greater China, where partners are responsible for development and commercialisation in key growth markets.
Leave a Reply